Annual report [Section 13 and 15(d), not S-K Item 405]

Note 13 - Income Taxes (Details Textual)

v3.25.3
Note 13 - Income Taxes (Details Textual) - USD ($)
 12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Deferred Tax Assets, Valuation Allowance $ 78,611,598 $ 72,502,102
Unrecognized Tax Benefits 0 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 0 0
Domestic Tax Jurisdiction [Member]    
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6,500,000  
Deferred Tax Assets, Valuation Allowance 75,500,000 69,000,000
Operating Loss Carryforwards $ 161,800,000 92,800,000
Open Tax Year 2006 2007 2015 2016 2017 2018 2019 2022 2023 2024  
Domestic Tax Jurisdiction [Member] | Tax Year 2024 to 2044 Expirations [Member]    
Operating Loss Carryforwards $ 28,100,000 49,500,000
Domestic Tax Jurisdiction [Member] | Tax Year, Not Subject to Expiration [Member]    
Operating Loss Carryforwards 133,700,000 43,300,000
Domestic Tax Jurisdiction [Member] | Tax Year 2038 to 2045 Expirations [Member]    
Tax Credit Carryforward, Amount 8,200,000  
Foreign Tax Jurisdiction [Member] | Veru Biopharma UK Limited [Member]    
Deferred Tax Assets, Valuation Allowance   400,000
Foreign Tax Jurisdiction [Member] | Subsidiary, Female Health Company Limited [Member]    
Deferred Tax Assets, Valuation Allowance $ 3,200,000 $ 3,200,000